AAFMAA Wealth Management & Trust LLC Trims Stake in Stryker Co. (NYSE:SYK)

AAFMAA Wealth Management & Trust LLC lessened its holdings in shares of Stryker Co. (NYSE:SYK) by 9.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,701 shares of the medical technology company’s stock after selling 713 shares during the quarter. Stryker makes up 1.1% of AAFMAA Wealth Management & Trust LLC’s portfolio, making the stock its 24th largest holding. AAFMAA Wealth Management & Trust LLC’s holdings in Stryker were worth $2,413,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dale Q Rice Investment Management Ltd purchased a new position in Stryker during the fourth quarter valued at approximately $587,000. Traveka Wealth LLC lifted its stake in shares of Stryker by 5.4% during the 4th quarter. Traveka Wealth LLC now owns 821 shares of the medical technology company’s stock valued at $296,000 after buying an additional 42 shares in the last quarter. Unique Wealth LLC boosted its holdings in Stryker by 11.0% in the 4th quarter. Unique Wealth LLC now owns 6,823 shares of the medical technology company’s stock worth $2,457,000 after buying an additional 676 shares during the period. Signet Financial Management LLC purchased a new stake in Stryker in the 4th quarter worth $230,000. Finally, PFW Advisors LLC bought a new stake in Stryker during the fourth quarter valued at about $1,350,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Citigroup increased their target price on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. BTIG Research boosted their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. UBS Group lifted their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, Robert W. Baird increased their price objective on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Stryker Trading Down 1.3 %

SYK opened at $360.96 on Tuesday. Stryker Co. has a 52 week low of $307.23 and a 52 week high of $398.20. The company has a market capitalization of $137.60 billion, a P/E ratio of 38.69, a PEG ratio of 2.82 and a beta of 0.95. The stock’s fifty day moving average is $375.28 and its two-hundred day moving average is $358.09. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.46 earnings per share. Analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.93%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is currently 36.01%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.